As of 2025-09-07, the Intrinsic Value of Marksans Pharma Ltd (MARKSANS.NS) is 98.46 INR. This MARKSANS.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 168.91 INR, the upside of Marksans Pharma Ltd is -41.70%.
The range of the Intrinsic Value is 86.72 - 115.09 INR
Based on its market price of 168.91 INR and our intrinsic valuation, Marksans Pharma Ltd (MARKSANS.NS) is overvalued by 41.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 86.72 - 115.09 | 98.46 | -41.7% |
| DCF (Growth 10y) | 115.50 - 153.74 | 131.46 | -22.2% |
| DCF (EBITDA 5y) | 202.27 - 294.71 | 228.67 | 35.4% |
| DCF (EBITDA 10y) | 201.54 - 304.83 | 234.20 | 38.7% |
| Fair Value | 209.96 - 209.96 | 209.96 | 24.30% |
| P/E | 176.87 - 245.85 | 206.55 | 22.3% |
| EV/EBITDA | 162.55 - 233.68 | 186.89 | 10.6% |
| EPV | 67.33 - 78.34 | 72.84 | -56.9% |
| DDM - Stable | 35.58 - 65.07 | 50.32 | -70.2% |
| DDM - Multi | 63.93 - 92.21 | 75.61 | -55.2% |
| Market Cap (mil) | 76,543.26 |
| Beta | 1.49 |
| Outstanding shares (mil) | 453.16 |
| Enterprise Value (mil) | 72,720.23 |
| Market risk premium | 8.31% |
| Cost of Equity | 17.07% |
| Cost of Debt | 8.76% |
| WACC | 16.91% |